Try Calculator
← Back to Compound Library HEALING / RECOVERY

Trevogrumab

Anti-Myostatin Monoclonal Antibody

Trevogrumab (development code REGN1033) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals that selectively binds and neutralizes myostatin (GDF-8), a key negative regulator of skeletal muscle growth and mass within the TGF-β superfamily. By binding circulating myostatin and preventing it from activating its receptor (ActRIIB), trevogrumab reduces downstream SMAD2/3 signaling and shifts the body’s signaling balance toward muscle protein synthesis and hypertrophy. Unlike short peptide fragments, small molecules, or gene therapy constructs, trevogrumab is a large IgG4-class biologic (approximately 150 kDa). This confers high target specificity, a long circulating half-life, and predictable pharmacokinetics. It was generated using Regeneron’s proprietary VelocImmune technology, which utilizes a genetically humanized mouse platform to produce optimized fully human antibodies. The clinical significance of trevogrumab has been dramatically elevated by the emergence of GLP-1 receptor agonist therapies for obesity. While drugs like semaglutide produce substantial weight loss, approximately one-third of that weight loss comes from lean mass (muscle) rather than fat. This muscle loss is a significant clinical concern, as it can impair metabolic health, physical function, and long-term outcomes. Trevogrumab is being investigated as a companion therapy to preserve lean mass during GLP-1-induced weight loss while enhancing fat mass reduction. In the Phase 2 COURAGE trial, combining semaglutide with trevogrumab prevented approximately half of the lean mass loss caused by semaglutide alone, while simultaneously increasing fat mass loss. These results have positioned trevogrumab at the forefront of an emerging field focused on the quality of weight loss, not just the quantity. Trevogrumab has also been investigated for muscle-wasting conditions including sarcopenia, orthopedic disuse atrophy, and sporadic inclusion body myositis. It is currently an investigational compound and has not been approved by any regulatory authority. The safety and efficacy of trevogrumab have not been evaluated by the FDA.

How It Works

Myostatin: The Muscle Growth Brake

Myostatin (GDF-8) is a secreted protein that acts as the body’s primary brake on skeletal muscle growth. Evolutionary pressures to minimize energy expenditure in times of food scarcity likely led to highly conserved pathways designed to limit muscle mass, since muscle is a major energy consumer. Myostatin suppresses muscle growth through several mechanisms: it inhibits satellite cell (muscle stem cell) activation, reduces muscle protein synthesis, and promotes catabolic signaling pathways that break down muscle tissue. Myostatin exerts these effects by binding to activin type II receptors (ActRIIA and ActRIIB) on muscle cells, which triggers intracellular SMAD2/3 phosphorylation. This SMAD signaling cascade suppresses the genes and pathways responsible for muscle growth and maintenance. Animals with naturally occurring myostatin mutations or genetic knockouts exhibit dramatically increased muscle mass, demonstrating the powerful inhibitory role myostatin plays.

Antibody Action: Neutralizing Myostatin

Trevogrumab works by binding directly to circulating myostatin with high specificity and affinity. Once bound, myostatin can no longer engage the ActRIIB receptor on muscle cells. This removes the myostatin-mediated brake on muscle growth and shifts the signaling balance toward muscle protein synthesis and hypertrophy pathways. The net cellular effects include increased muscle fiber cross-sectional area, enhanced anabolic signaling, and reduced myostatin-mediated suppression of muscle growth. Critically, trevogrumab is highly specific to GDF-8. It has no cross-reactivity to GDF-11, a closely related member of the TGF-β family. This selectivity makes it a cleaner mechanistic tool compared to non-specific ActRIIB blockers or broad follistatin-based approaches, which inhibit multiple TGF-β family ligands simultaneously.

Downstream Signaling

By neutralizing myostatin, trevogrumab reduces SMAD2/3 phosphorylation in skeletal muscle. This reduction in inhibitory signaling allows increased activation of the Akt/mTOR pathway, the primary driver of muscle protein synthesis. The result is a favorable shift in the balance between muscle protein synthesis and degradation, promoting net muscle growth or preservation depending on the physiological context.

Dual Blockade: The Activin A Connection

Research has established that myostatin is not the only negative regulator of muscle mass signaling through ActRIIB. Activin A is the second major ligand that suppresses muscle growth through the same receptor pathway. When ActRIIB is blocked broadly, the muscle growth response is approximately double that of blocking myostatin alone. Regeneron’s research program has therefore developed garetosmab (REGN2477), an anti-activin A antibody, to be used in combination with trevogrumab. This dual blockade approach matches the muscle- preserving effects of broad receptor blockade while maintaining the specificity and controllability of targeted ligand neutralization.

Pharmacokinetic Profile

As a large IgG4 monoclonal antibody, trevogrumab has a long circulating half-life consistent with its antibody class, allowing for infrequent dosing on the order of every two to four weeks via subcutaneous injection. The pharmacokinetics are predictable and well-characterized, and the antibody’s effects are reversible with clearance, providing controllable dosing that can be adjusted or discontinued as needed.

Benefits

Lean Mass Preservation During Weight Loss

The most clinically significant benefit demonstrated to date is the preservation of lean mass during GLP-1 receptor agonist-induced weight loss. In the Phase 2 COURAGE trial, combining semaglutide with trevogrumab prevented approximately half of the lean mass that would otherwise be lost with semaglutide alone. This is critical because lean mass loss during weight loss impairs metabolic rate, physical function, and long-term weight maintenance.

Enhanced Fat Mass Loss

Beyond preserving lean mass, the addition of trevogrumab to semaglutide actually increased the proportion of weight lost as fat. In the COURAGE trial, the higher-dose combination shifted the composition of weight loss from 67% fat (semaglutide alone) to approximately 82% fat. The triplet combination (adding garetosmab) achieved approximately 93% fat composition of total weight loss. This improved quality of weight loss may have significant implications for metabolic health outcomes.

Muscle Hypertrophy

In preclinical studies, chronic treatment of mice with REGN1033 increased muscle fiber size, muscle mass, and force production. In aged mice, REGN1033 increased muscle mass and strength and improved physical performance during treadmill exercise. In the Phase 1 clinical trial in healthy postmenopausal women, trevogrumab alone produced dose-dependent increases in MRI-quantified thigh muscle volume, and the combination with garetosmab produced substantial increases in total body muscle volume and lean body mass measured by DXA.

Muscle Atrophy Prevention

Preclinical research demonstrated that REGN1033 prevented the loss of muscle mass induced by immobilization, glucocorticoid treatment, and hindlimb unweighting. It also increased the gain of muscle mass during recovery from pre-existing atrophy. These findings support potential applications in disuse atrophy from injury or surgery, glucocorticoid-induced muscle wasting, and age-related sarcopenia.

Metabolic Improvements

In the COURAGE trial, numerical improvements in metabolic and lipid parameters were observed across all treatment groups, including improvements in waist circumference, blood pressure, cholesterol, triglycerides, and hemoglobin A1C. In preclinical studies, muscle preservation during GLP-1 therapy was associated with enhanced metabolic benefits, as maintaining metabolically active muscle tissue supports better glucose regulation and energy expenditure.

What the Science Shows

Trevogrumab has been evaluated in preclinical models, Phase 1 clinical trials, and the pivotal Phase 2 COURAGE trial. The body of evidence spans from fundamental molecular pharmacology to large-scale randomized controlled human studies.

Phase 2 COURAGE Trial (2025) – Obesity and GLP-1 Combination

The COURAGE trial is a randomized, double-blind, placebo-controlled Phase 2 study investigating combinations of semaglutide (2.4 mg) with trevogrumab (200 mg or 400 mg) with or without garetosmab (10 mg/kg) in patients with obesity (BMI ≥30 kg/m²). The trial enrolled approximately 600 patients across four treatment arms. Complete 26-week results presented at the European Association for the Study of Diabetes (EASD) in September 2025 demonstrated:

Endpoint Semaglutide Lower-Dose Higher-Dose Triplet Alone Combo Combo Lean mass change -6.5% -3.3% -3.8% -2.0% Lean mass loss (kg) -3.3 kg (33%) -1.5 kg (17%) -1.9 kg (18%) -0.9 kg (7%) Fat mass change -15.7% -17.3% -19.1% -27.1% Fat mass loss (kg) -6.7 kg (67%) -7.6 kg (83%) -8.5 kg (82%) -11.8 kg (93%) Body weight change -10.6% -9.9% -11.1% -13.4%

Lean mass and fat mass were measured using dual-energy X-ray absorptiometry (DXA). The lower-dose and higher-dose combo results for lean mass preservation were statistically significant (p<0.001). The triplet achieved the greatest lean mass preservation and fat mass reduction, though with higher discontinuation rates.

Phase 1 Trial in Postmenopausal Women (NCT02943239) This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of trevogrumab alone, garetosmab alone, and the combination at escalating doses in healthy postmenopausal women. The study was the first clinical trial to demonstrate that GDF-8 and activin A work together to regulate muscle growth in humans. Combination blockade with both antibodies led to substantial dose-dependent increases in MRI-quantified thigh muscle volume that exceeded the effects of either antibody alone. Increases in total body muscle volume and lean body mass were also observed using DXA. No subjects tested positive for anti-drug antibodies post-treatment.

Preclinical Studies: Muscle Hypertrophy and Atrophy Prevention Latres et al. characterized REGN1033 extensively in mouse models. Surface plasmon resonance confirmed high-affinity binding to myostatin, and cell-based assays demonstrated potent inhibition of SMAD2/3 signaling. In vivo, chronic treatment increased muscle fiber size, muscle mass, and force production in young mice. In models of muscle atrophy (immobilization, hindlimb suspension, and dexamethasone-induced wasting), REGN1033 prevented muscle loss

and accelerated recovery from pre-existing atrophy. In aged mice, REGN1033 increased muscle mass and strength and improved treadmill exercise performance.

Preclinical Studies: GLP-1 Combination in Mice and Primates

A 2025 study published in Nature Communications examined the combination of GDF-8 and activin A blockade with GLP-1 receptor agonism in diet-induced obese mice and obese cynomolgus monkeys. The study demonstrated that dual antibody blockade during GLP-1 therapy prevented muscle loss and even increased muscle mass, while enhancing fat mass loss. The muscle preservation was associated with improved metabolic outcomes. These preclinical results provided the scientific rationale for the COURAGE clinical trial.

Proteomic Analysis

A high-resolution mass spectrometry study using SILAC mouse technology compared the muscle proteome of myostatin knockout mice to mice treated with REGN1033. While genetic myostatin knockout produced a two-fold increase in muscle mass with extensive proteomic changes (12% of quantified proteins altered), pharmacologic inhibition with REGN1033 produced significant muscle hypertrophy with minimal proteomic disruption (less than 1% of proteins altered). This finding is reassuring for therapeutic applications, as it suggests that antibody-mediated myostatin inhibition increases muscle mass through a more targeted and less disruptive mechanism than complete genetic elimination.

Sporadic Inclusion Body Myositis (sIBM) A Phase 2 randomized, double-blind, placebo-controlled study (NCT03710941) evaluated the combination of garetosmab and trevogrumab administered intravenously in patients with sporadic inclusion body myositis, a progressive muscle-wasting disorder. This study reflects the broader therapeutic potential of myostatin inhibition beyond obesity.

Dosing Protocol

Trevogrumab is an investigational biologic administered by injection in supervised clinical settings. The following dosing information is derived from published clinical trial protocols and is provided for research reference only. This compound is not available for general use.

COURAGE Trial Dosing (Obesity / GLP-1 Combination) Treatment Arm Trevogrumab Dose Additional Agents Lower-dose combo 200 mg SC Semaglutide 2.4 mg Higher-dose combo 400 mg SC Semaglutide 2.4 mg Triplet 400 mg SC Semaglutide 2.4 mg + garetosmab 10 mg/kg

The trial consisted of a 26-week weight-loss phase followed by a 26-week weight-maintenance phase. During the maintenance phase, patients received either higher-dose trevogrumab monotherapy or placebo.

Earlier Clinical Programs

Earlier healthy-volunteer and sarcopenia programs evaluated REGN1033 as a single agent at dose ranges of 100 to 400 mg administered subcutaneously every two to four weeks. These studies focused on changes in lean body mass and thigh muscle volume and established the dose ranges and feasibility of modulating lean mass endpoints.

Route of Administration

of IgG4 antibodies

Important Context

Trevogrumab is a pharmaceutical-grade biologic, not a typical research peptide. It is produced through cell-line expression (not solid-phase peptide synthesis like short peptides) and requires complex manufacturing, quality control, and cold chain storage. It is not available through research peptide suppliers and is administered only within supervised clinical trial settings.

Side Effects and Safety Profile

Safety data are available from the Phase 2 COURAGE trial and earlier clinical studies. The combination of semaglutide with trevogrumab was generally well-tolerated.

Common Adverse Events (COURAGE Trial, ≥5% in Any Group)

Most of these events were mild to moderate in severity. Many of these adverse events are also commonly associated with semaglutide (GLP-1 receptor agonist) therapy and may not be directly attributable to trevogrumab.

Triplet Combination Safety Considerations

The triplet combination (semaglutide plus trevogrumab plus garetosmab) had a substantially higher rate of discontinuations due to tolerability issues and other adverse events compared to the dual combinations. Two deaths occurred in the triplet group: one due to an undetermined cause in a patient with multiple cardiovascular risk factors, and one due to cardiac arrest in a patient with a history of cardiovascular disease. Regeneron has not identified a causal association between treatment and these events.

Phase 1 Safety Data

In the Phase 1 trial in healthy postmenopausal women, trevogrumab alone and in combination with garetosmab was generally well-tolerated. No subjects developed anti-drug antibodies post- treatment, and no observable trends in body weight were noted outside of expected pharmacodynamic effects.

Theoretical Considerations

could theoretically disrupt tissue homeostasis

hypertrophy

characterized

in animal models, which is why early trials enrolled postmenopausal women

Contraindications and Precautions

As an investigational compound, formal contraindications have not been established through regulatory approval. The following precautions are based on clinical trial exclusion criteria and theoretical considerations.

Populations Studied with Caution

preclinical concerns about activin A blockade and reproductive function)

populations

Theoretical Precautions

Monitoring Considerations

Comparison to Similar Compounds

Trevogrumab represents one of several approaches to inhibiting the myostatin/activin pathway. Understanding the differences in mechanism, specificity, and controllability is important for evaluating each approach.

Feature Trevogrumab Follistatin Bimagrumab Apitegromab ACE-031 / (FLGR242- Sotatercept type) Type Anti-GDF8 Gene construct / Anti-ActRII Anti- ActRIIA-Fc mAb protein mAb proMyostatin trap mAb Myostatin Yes Yes Yes (indirect) Yes Yes (indirect) inhibition Activin A No Yes Yes No Yes inhibition Selectivity High Broad Broad High Broad Controllability High Low (sustained High High High (reversible) expression) (reversible) (reversible) (reversible) Clinical stage Phase 2 Experimental Phase 2/3 Phase 3 Approved (SMA) (PAH)

Trevogrumab Versus Follistatin-Based Approaches

The most critical distinction is controllability versus potency. Trevogrumab is a dial: controlled dosing, finite half-life, and reversible effects. Gene-based follistatin expression is a switch: sustained protein production, longer biological persistence, and difficulty titrating once delivered. Follistatin’s broader inhibition (binding myostatin, activin A, and potentially other TGF-β ligands) may amplify hypertrophy but also increases biological ripple effects, including potential impacts on the reproductive axis, inflammatory signaling, and metabolic regulation.

The Size Versus Strength Distinction

A critical insight from the research literature is that increasing muscle size does not automatically equal functional strength improvement. Clinical development history with myostatin inhibitors has consistently shown increases in lean mass with mixed or modest functional strength outcomes. Strength depends on neuromuscular adaptation, fiber type shifts, myonuclear domain dynamics, and tendon adaptation. This distinction remains an active area of investigation.

Research Considerations and Best Practices

Analytical Verification

Because trevogrumab is a large antibody biologic, reproducibility in research depends heavily on the glycosylation profile, structural integrity, proper storage conditions, and aggregation status. Analytical verification matters significantly more with monoclonal antibodies than with short peptides. Researchers should verify product identity and integrity before use in any experimental system.

Key Research Endpoints

Researchers evaluating trevogrumab in controlled settings typically assess:

Interpreting Results in Context

Myostatin exists for a reason. Completely removing it or broadly suppressing related ligands can disrupt tissue homeostasis, alter tendon-to-muscle balance, and change metabolic regulation. Research findings should be interpreted in the context of the specific experimental model, the degree and duration of inhibition, and the distinction between lean mass changes and functional outcomes.

Combination Therapy Considerations

The COURAGE trial data suggest that the most promising application of trevogrumab may be in combination with GLP-1 receptor agonists rather than as a standalone muscle-building agent. The concept of improving the quality of weight loss by preserving muscle while enhancing fat loss represents a paradigm shift in obesity treatment. Future research should consider this combination context when designing studies.

Storage and Handling

As a monoclonal antibody biologic, trevogrumab requires careful handling to maintain structural integrity and biological activity.

General Antibody Storage Principles

Critical Quality Attributes

The biological activity of monoclonal antibodies depends on maintaining proper protein folding, glycosylation, and absence of aggregation. Temperature excursions, freeze-thaw cycles, and physical stress can compromise these attributes and reduce or eliminate therapeutic activity. Storage and handling protocols must be strictly followed.

Legal Status

United States: Trevogrumab is an investigational drug. It has not been approved by the FDA. It is available only through participation in authorized clinical trials conducted by Regeneron Pharmaceuticals. It is not a scheduled controlled substance. International: Not approved by any regulatory authority. Clinical trials have been conducted in the United States and other countries under investigational new drug applications. Research Availability: Trevogrumab (REGN1033) is available from specialized research reagent suppliers for in vitro and in vivo research use only. It is explicitly not intended for human use outside of authorized clinical trials.

Important Distinction: This is pharmaceutical-grade biologic territory, not typical research peptide chemistry. The compound requires complex cell-line manufacturing, not solid-phase peptide synthesis. Its availability, cost, and handling requirements are fundamentally different from short research peptides.

Frequently Asked Questions

What is the difference between trevogrumab and a myostatin-inhibiting peptide? Trevogrumab is a large IgG4 monoclonal antibody (approximately 150 kDa), not a short peptide fragment. It offers high target specificity, a long circulating half-life, and predictable pharmacokinetics. Short peptide-based myostatin inhibitors have different binding characteristics, shorter half-lives, and different manufacturing requirements. Does blocking myostatin automatically increase strength? Not necessarily. Clinical research has consistently shown that myostatin inhibition increases lean mass, but functional strength improvements have been mixed or modest. Strength depends on neuromuscular adaptation, fiber type composition, and tendon adaptation, not muscle size alone. Can I obtain trevogrumab for personal use? No. Trevogrumab is available only through authorized clinical trials. Research-grade material available from reagent suppliers is strictly for laboratory research and is not intended for human use. How does the COURAGE trial combination work? In the COURAGE trial, semaglutide (a GLP-1 receptor agonist) drives weight loss through appetite suppression, while trevogrumab preserves lean mass by blocking myostatin’s muscle- suppressing signal. The result is weight loss that is proportionally more fat and less muscle compared to semaglutide alone. What is garetosmab, and why is it combined with trevogrumab? Garetosmab (REGN2477) is an anti-activin A monoclonal antibody. Activin A is the second major negative regulator of muscle growth. Blocking both myostatin and activin A together produces greater muscle preservation than blocking either alone, because these two ligands are the dominant negative regulators acting through the ActRIIB receptor pathway. Is trevogrumab the same as REGN1033? Yes. Trevogrumab is the International Nonproprietary Name (INN), and REGN1033 is the development code assigned by Regeneron Pharmaceuticals. They refer to the same compound. What happens during the maintenance phase of the COURAGE trial?

After the 26-week weight-loss phase, patients enter a 26-week weight-maintenance phase in which they receive either higher-dose trevogrumab monotherapy or placebo. Data from this phase will help determine whether trevogrumab can maintain the improvements in body composition after the active weight-loss period.

References

1. Regeneron Pharmaceuticals. Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 Receptor Agonist-Induced Weight Loss by Preserving Lean Mass, Presented at EASD. Press Release, September 17, 2025.

2. Latres E, Pangilinan J, Engstrom L, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skeletal Muscle. 2015;5:34.

3. Dagdeviren S, Jung DY, Lee E, et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications. 2025;16:4422.

4. Bhatt SP, Engstrom L, Engstrom K, et al. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. Nature Communications. 2025;16:5108.

5. Latres E, Mastaitis J, Morber S, et al. Muscle proteomics reveals that a selective myostatin antagonist increases muscle mass without changing protein quality. Proteomics. 2017;17(3–4):1600260.

6. Saitoh M, Ishida J, Ebner N, et al. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. JCSM Rapid Communications. 2017;2(1):1–10.

7. Regeneron Pharmaceuticals. Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide-Induced Weight Loss by Preserving Lean Mass. Press Release, June 2025.

8. ClinicalTrials.gov Identifier: NCT06299098. A Study to Test if Trevogrumab or Trevogrumab and Garetosmab Can Improve the Quality of Weight Loss From Wegovy in Adults With Obesity (COURAGE).

9. ClinicalTrials.gov Identifier: NCT02943239. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN1033 and REGN2477.

10. ClinicalTrials.gov Identifier: NCT03710941. Study of REGN2477 and REGN1033 in Patients With Sporadic Inclusion Body Myositis.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch